Shares of Cupid Ltd saw a positive uptick of 2% in today's trading session after the company signaled exceptional growth ahead. Investors reacted favorably to the news that the firm now anticipates its first-quarter revenue for FY27 to clear the Rs 150 crore milestone.
Building on this momentum, leadership has revised its full-year revenue guidance for FY27, setting a target in excess of Rs 660 crore. Management attributes this renewed optimism to a strategy of aggressive diversification and increasing brand visibility within the global healthcare sector.
The company’s core condom and lubricant lines remain the primary engines of this expansion. However, the firm is also reporting significant traction within its In-Vitro Diagnostics (IVD) segment, suggesting a broader base for future earnings.
With market confidence rising, Cupid appears positioned to leverage new international opportunities to sustain its current growth trajectory. Analysts are closely monitoring these developments as the company shifts its focus toward scaling its specialized healthcare portfolio.
